BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Oct. 6, 2020
View Archived Issues
Targeted delivery improves checkpoint blockade
Read More
A potent and selective allosteric inhibitor of SHP2 that overcomes tumor resistance to osimertinib
Read More
Carcinogens need not be mutagens
Read More
Lantern Pharma and Georgetown University advance development of LP-184
Read More
New JAK inhibitors identified at Beijing Scitech-Mq Pharmaceuticals
Read More
Patient screening ongoing in phase IIa study of IP-2018
Read More
NervGen provides updates regarding development of NVG-291
Read More
First-in-human data for the anti-BCMA antibody-drug conjugate AMG-224
Read More
Hangzhou Innogate Pharma discovers ALK/mutant EGFR/MAP4K1 inhibitors
Read More
Kyushu University presents new lysosomal alpha-glucosidase inhibitors
Read More
Central China Normal University synthesizes new TRK inhibitors
Read More
Three win Nobel Prize for hepatitis C discoveries
Read More
NuvoBio patents N-lysine methyltransferase KMT5A inhibitors
Read More
Pralsetinib shows promising activity in RET-mutant MTC in the phase I/II ARROW trial
Read More
PALLAS: palbociclib not beneficial in early breast cancer treated with endocrine therapy
Read More
miRagen to discontinue internal development of cobomarsen for CTCL
Read More
NMD Pharma begins phase I/IIa trial of NMD-670 to treat symptoms of myasthenia gravis
Read More
Santhera ends development of idebenone following phase III futility analysis
Read More
Phase I data for LXH-254 plus LTT-462 in patients with KRAS- or BRAF-mutant NSCLC
Read More
Clinical results reported for anti-TIGIT antibody vibostolimab +/- pembrolizumab in NSCLC
Read More
FDA approves Opdivo + Yervoy for unresectable malignant pleural mesothelioma
Read More
Promising data seen in phase I studies of bispecific HER2/4-1BB molecule PRS-343
Read More
Tarsius reports phase I/II data on TRS-01 in active noninfectious anterior uveitis
Read More
Kodiak Sciences begins pivotal studies of KSI-301 in DME and RVO
Read More